Annual report
2158.TEDINET S100YGJA
Period2025-04-01 → 2026-03-31
Filed2026-06-23
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 146
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥7.6bn | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥6.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥7.4bn | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥7.2bn | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥10.9bn | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥739m | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥528m | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥675m | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥544m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥168m | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.3bn | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.7bn | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥665m | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥246m | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥544m | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥555m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥2.8bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥1.7bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.3bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥544m | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥555m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥9.2bn | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥6.5bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥7.5bn | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥9.1bn | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥11.8bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.4bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥3.2bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥3.8bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.2bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥2.8bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥5.1bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥6.4bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.7bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.6bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.7bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.6bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.5bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥3.5bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥258m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥753m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.7bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥915m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.4bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.5bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥254m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥182m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥625m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥618m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥1.3bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥913m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥34m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥606m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.5bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥13.86 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥14.1 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-72.25 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-43.27 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥33.35 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥13.86 | 2025-04-01 → 2026-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥14.1 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥33.11 | 2021-04-01 → 2022-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥93.33 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥75.38 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥66.37 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥123.5 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥160.47 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 39.7% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.7% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.2% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.3% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 16.4% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 19.9% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 24.3% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 272 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 206 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 225 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 288 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 310 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥5.0bn | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥4.7bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥5.0bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥4.4bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥5.7bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | ¥674m | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥591m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥823m | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥587m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥294m | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥19m | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.2bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥857m | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥219m | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥860m | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥152m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | −¥6.7bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥9m | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥968m | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥8.2bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥5.5bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥7.5bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥12.6bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥13.5bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥4.6bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥2.9bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥3.5bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥2.6bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥2.6bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥9.0bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥9.2bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.1bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.8bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥21.89 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥3.87 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-170.18 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-0.24 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.66 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥21.89 | 2025-04-01 → 2026-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥3.87 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥24.48 | 2021-04-01 → 2022-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥7 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥85.68 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥59.98 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥59.98 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥225.08 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥231.14 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 41.1% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.9% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.6% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.1% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.1% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 30.1% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.5% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.3% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 39,412,000 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 39,356,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 39,355,000 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 39,332,000 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 39,314,000 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 170 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 164 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 171 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 204 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 186 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 62
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2025-04-01 → 2026-03-31 | −¥12m |
| Reconciling Itemsreconciling | depreciation | 2025-04-01 → 2026-03-31 | −¥163,000 |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥12m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥12m |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | −¥12m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥12m |
| Digital Transformationreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥95m |
| Digital Transformationreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥29m |
| Digital Transformationreportable segment | employees | at 2026-03-31 | 104 pure |
| Digital Transformationreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥2.6bn |
| Digital Transformationreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥2.6bn |
| Digital Transformationreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥12m |
| Digital Transformationreportable segment | segment assets | at 2026-03-31 | ¥4.0bn |
| Digital Transformationreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥162m |
| Life Sciencereportable segment | capex | 2025-04-01 → 2026-03-31 | ¥290m |
| Life Sciencereportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥40m |
| Life Sciencereportable segment | employees | at 2026-03-31 | 53 pure |
| Life Sciencereportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥1.0bn |
| Life Sciencereportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥1.0bn |
| Life Sciencereportable segment | segment assets | at 2026-03-31 | ¥1.7bn |
| Life Sciencereportable segment | segment profit | 2025-04-01 → 2026-03-31 | −¥16m |
| Risk Managementreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥531m |
| Risk Managementreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥307m |
| Risk Managementreportable segment | employees | at 2026-03-31 | 115 pure |
| Risk Managementreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥4.0bn |
| Risk Managementreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥4.0bn |
| Risk Managementreportable segment | segment assets | at 2026-03-31 | ¥3.5bn |
| Risk Managementreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥606m |
| —segment total | capex | 2025-04-01 → 2026-03-31 | ¥916m |
| —segment total | depreciation | 2025-04-01 → 2026-03-31 | ¥376m |
| —segment total | revenue | 2025-04-01 → 2026-03-31 | ¥7.7bn |
| —segment total | revenue external | 2025-04-01 → 2026-03-31 | ¥7.6bn |
| —segment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥12m |
| —segment total | segment assets | at 2026-03-31 | ¥9.2bn |
| —segment total | segment profit | 2025-04-01 → 2026-03-31 | ¥751m |
| Digital Transformationreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥22m |
| Digital Transformationreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥14m |
| Digital Transformationreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥371m |
| Digital Transformationreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥371m |
| Digital Transformationreportable segment | segment assets | at 2025-03-31 | ¥268m |
| Digital Transformationreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥100m |
| Life Sciencereportable segment | capex | 2024-04-01 → 2025-03-31 | ¥59m |
| Life Sciencereportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥8m |
| Life Sciencereportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥355m |
| Life Sciencereportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥355m |
| Life Sciencereportable segment | segment assets | at 2025-03-31 | ¥1.2bn |
| Life Sciencereportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥232m |
| Risk Managementreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥189m |
| Risk Managementreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥323m |
| Risk Managementreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥5.4bn |
| Risk Managementreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥5.4bn |
| Risk Managementreportable segment | segment assets | at 2025-03-31 | ¥5.0bn |
| Risk Managementreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥659m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥271m |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥345m |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥6.1bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥6.1bn |
| —segment total | segment assets | at 2025-03-31 | ¥6.5bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥528m |
| Digital Transformationreportable segment | employees | at 2026-03-31 | 11 pure |
| Life Sciencereportable segment | employees | at 2026-03-31 | 53 pure |
| Risk Managementreportable segment | employees | at 2026-03-31 | 106 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,533
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of treasury stock fin cf | CurrentYearDuration | -199934000 | JPY |
| Other net fin cf | Prior1YearDuration | -722000 | JPY |
| Other net fin cf | CurrentYearDuration | -57456000 | JPY |
| Net cash provided by used in financing activities | Prior1YearDuration | -913281000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | 1335825000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YearDuration | -30579000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYearDuration | 22148000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YearDuration | -444618000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | -870032000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 3039480000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 2594862000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 2594862000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 1724829000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 5 | |
| Directors compensations sga | Prior1YearDuration | 156939000 | JPY |
| Directors compensations sga | CurrentYearDuration | 166030000 | JPY |
| Salaries and allowances sga | Prior1YearDuration | 1019581000 | JPY |
| Salaries and allowances sga | CurrentYearDuration | 928988000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YearDuration | 3418000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYearDuration | 11153000 | JPY |
| Provision for bonuses sga | Prior1YearDuration | 84737000 | JPY |
| Provision for bonuses sga | CurrentYearDuration | 78493000 | JPY |
| Retirement benefit expenses sga | Prior1YearDuration | 23350000 | JPY |
| Retirement benefit expenses sga | CurrentYearDuration | 21875000 | JPY |
| Depreciation sga | Prior1YearDuration | 33729000 | JPY |
| Depreciation sga | CurrentYearDuration | 136552000 | JPY |
| Commission fee sga | Prior1YearDuration | 693171000 | JPY |
| Commission fee sga | CurrentYearDuration | 639747000 | JPY |
| Consulting fee sga | Prior1YearDuration | 170499000 | JPY |
| Consulting fee sga | CurrentYearDuration | 196252000 | JPY |
| Research and development expenses sga | Prior1YearDuration | 75561000 | JPY |
| Research and development expenses sga | CurrentYearDuration | 231173000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E05700-000LifeScienceReportableSegmentMember | 354596000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E05700-000RiskManagementReportableSegmentMember | 5374219000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E05700-000DigitalTransformationReportableSegmentMember | 370587000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReportableSegmentsMember | 6099403000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YearDuration | 6099403000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E05700-000LifeScienceReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E05700-000RiskManagementReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E05700-000DigitalTransformationReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration | － | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E05700-000LifeScienceReportableSegmentMember | 354596000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E05700-000RiskManagementReportableSegmentMember | 5374219000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E05700-000DigitalTransformationReportableSegmentMember | 370587000 | JPY |
| Net sales | Prior1YearDuration_ReportableSegmentsMember | 6099403000 | JPY |
| Net sales | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YearDuration | 6099403000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |